These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 27741010)

  • 81. FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer.
    Song SY; Kim JH; Ryu JS; Lee GH; Kim SB; Park SI; Song HY; Cho KJ; Ahn SD; Lee SW; Shin SS; Choi EK
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1053-9. PubMed ID: 15964705
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Molecular Markers for the Prediction of Minor Response to Neoadjuvant Chemoradiation in Esophageal Cancer: Results of the Prospective Cologne Esophageal Response Prediction (CERP) Study.
    Bollschweiler E; Hölscher AH; Herbold T; Metzger R; Alakus H; Schmidt H; Drebber U; Warnecke-Eberz U
    Ann Surg; 2016 Nov; 264(5):839-846. PubMed ID: 27741011
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Magnetic Resonance Tumor Regression Grade and Residual Mucosal Abnormality as Predictors for Pathological Complete Response in Rectal Cancer Postneoadjuvant Chemoradiotherapy.
    Bhoday J; Smith F; Siddiqui MR; Balyasnikova S; Swift RI; Perez R; Habr-Gama A; Brown G
    Dis Colon Rectum; 2016 Oct; 59(10):925-33. PubMed ID: 27602923
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Predictive value of initial PET-SUVmax in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma.
    Rizk NP; Tang L; Adusumilli PS; Bains MS; Akhurst TJ; Ilson D; Goodman K; Rusch VW
    J Thorac Oncol; 2009 Jul; 4(7):875-9. PubMed ID: 19487968
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Value of combined interpretation of computed tomography response and positron emission tomography response for prediction of prognosis after neoadjuvant chemotherapy in non-small cell lung cancer.
    Lee HY; Lee HJ; Kim YT; Kang CH; Jang BG; Chung DH; Goo JM; Park CM; Lee CH; Kang KW
    J Thorac Oncol; 2010 Apr; 5(4):497-503. PubMed ID: 20195167
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Positron emission tomographic scanning predicts survival after induction chemotherapy for esophageal carcinoma.
    Port JL; Lee PC; Korst RJ; Liss Y; Meherally D; Christos P; Mazumdar M; Altorki NK
    Ann Thorac Surg; 2007 Aug; 84(2):393-400; discussion 400. PubMed ID: 17643605
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Neither FDG-PET Nor CT can distinguish between a pathological complete response and an incomplete response after neoadjuvant chemoradiation in locally advanced rectal cancer: a prospective study.
    Guillem JG; Ruby JA; Leibold T; Akhurst TJ; Yeung HW; Gollub MJ; Ginsberg MS; Shia J; Suriawinata AA; Riedel ER; Mazumdar M; Saltz LB; Minsky BD; Nash GM; Paty PB; Temple LK; Weiser MR; Larson SM
    Ann Surg; 2013 Aug; 258(2):289-95. PubMed ID: 23187748
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Does the computed tomography perfusion imaging improve the diagnostic accuracy in the response evaluation of esophageal carcinoma to the neoadjuvant chemoradiotherapy? Preliminary study.
    Djuric-Stefanovic A; Saranovic D; Micev M; Stankovic V; Plesinac-Karapandzic V; Pesko P; Stojakov D; Sabljak P; Bjelovic M
    J BUON; 2014; 19(1):237-44. PubMed ID: 24659670
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
    Castoro C; Scarpa M; Cagol M; Ruol A; Cavallin F; Alfieri R; Zanchettin G; Rugge M; Ancona E
    Ann Surg Oncol; 2011 Dec; 18(13):3743-54. PubMed ID: 21556952
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Endoscopic biopsy and EUS for the detection of pathologic complete response after neoadjuvant chemoradiotherapy in esophageal cancer: a systematic review and meta-analysis.
    van Rossum PSN; Goense L; Meziani J; Reitsma JB; Siersema PD; Vleggaar FP; van Vulpen M; Meijer GJ; Ruurda JP; van Hillegersberg R
    Gastrointest Endosc; 2016 May; 83(5):866-79. PubMed ID: 26632523
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Different accuracy of endosonographic tumor staging after neoadjuvant chemotherapy and chemoradiotherapy in esophageal cancer.
    Bohle W; Kasper M; Zoller WG
    Surg Endosc; 2016 Jul; 30(7):2922-8. PubMed ID: 26487231
    [TBL] [Abstract][Full Text] [Related]  

  • 92. PET/CT-based metabolic tumour volume for response prediction of neoadjuvant chemoradiotherapy in oesophageal carcinoma.
    Blom RL; Steenbakkers IR; Lammering G; Vliegen RF; Belgers EJ; de Jonge C; Schreurs WM; Nap M; Sosef MN
    Eur J Nucl Med Mol Imaging; 2013 Oct; 40(10):1500-6. PubMed ID: 23764889
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Diffusion-weighted magnetic resonance imaging for the prediction of pathologic response to neoadjuvant chemoradiotherapy in esophageal cancer.
    van Rossum PS; van Lier AL; van Vulpen M; Reerink O; Lagendijk JJ; Lin SH; van Hillegersberg R; Ruurda JP; Meijer GJ; Lips IM
    Radiother Oncol; 2015 May; 115(2):163-70. PubMed ID: 26002307
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Endoscopic and Imaging Predictors of Complete Pathologic Response After Chemoradiation for Esophageal Cancer.
    Uberoi GS; Uberoi AS; Bhutani MS
    Curr Gastroenterol Rep; 2017 Oct; 19(11):57. PubMed ID: 28983771
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Early response evaluation of neoadjuvant therapy with PET/MRI to predict resectability in patients with adenocarcinoma of the esophagogastric junction.
    Belmouhand M; Löfgren J; Johannesen HH; Baeksgaard L; Gutte H; Tariq K; Achiam MP
    Abdom Radiol (NY); 2019 Mar; 44(3):836-844. PubMed ID: 30467723
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Nomogram for predicting pathologically complete response after neoadjuvant chemoradiotherapy for oesophageal cancer.
    Toxopeus EL; Nieboer D; Shapiro J; Biermann K; van der Gaast A; van Rij CM; Steyerberg EW; van Lanschot JJ; Wijnhoven BP
    Radiother Oncol; 2015 Jun; 115(3):392-8. PubMed ID: 26116340
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Early prediction of residual disease after neoadjuvant chemoradiotherapy and cetuximab for locally advanced esophageal cancer using
    Brenner B; Kundel Y; Cohen Z; Brand H; Gordon N; Sulkes A; Morgenstern S; Menasherov N; Kashtan H; Groshar D; Domachevsky L; Bernstine H
    J Gastrointest Oncol; 2022 Dec; 13(6):2721-2735. PubMed ID: 36636052
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Dynamic contrast-enhanced MRI for treatment response assessment in patients with oesophageal cancer receiving neoadjuvant chemoradiotherapy.
    Heethuis SE; van Rossum PS; Lips IM; Goense L; Voncken FE; Reerink O; van Hillegersberg R; Ruurda JP; Philippens ME; van Vulpen M; Meijer GJ; Lagendijk JJ; van Lier AL
    Radiother Oncol; 2016 Jul; 120(1):128-35. PubMed ID: 27296409
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol.
    Noordman BJ; Shapiro J; Spaander MC; Krishnadath KK; van Laarhoven HW; van Berge Henegouwen MI; Nieuwenhuijzen GA; van Hillegersberg R; Sosef MN; Steyerberg EW; Wijnhoven BP; van Lanschot JJ;
    JMIR Res Protoc; 2015 Jun; 4(2):e79. PubMed ID: 26121676
    [TBL] [Abstract][Full Text] [Related]  

  • 100. CT-based radiomic signatures for prediction of pathologic complete response in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy.
    Yang Z; He B; Zhuang X; Gao X; Wang D; Li M; Lin Z; Luo R
    J Radiat Res; 2019 Jul; 60(4):538-545. PubMed ID: 31111948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.